Neuroimmunology Drug Development – Thematic Research
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Neuroimmunology Drug Development Market Overview
Neuroimmune communication is complex, bidirectional, and mediated across both neural and humoral pathways. A neuroimmunology drug is an agent that aims to regulate immune system activity to treat neurological diseases with underlying immune pathologies. Of the innovator products marketed for the eight key indications covered in this report, the majority are indicated for multiple sclerosis (MS), followed by neuromyelitis optica spectrum disorder (NMOSD), Alzheimer’s disease (AD), and for myasthenia gravis (MG). Most marketed neuroimmunology products are small molecules, followed by mAbs and recombinant proteins. The list of pipeline neuroimmunology therapeutics currently in development is extensive and holds numerous novel approaches to targeting neurological indications.
The neuroimmunology drug development thematic research report focuses on neuroimmunology drug development within eight key indications (MS, NMOSD, GBS, CIDP, MG, AD/MCI, PD, and ALS) across eight major pharmaceutical markets (8MM: the US, 4EU, the UK, Japan, and China).
What are the key trends in the neuroimmunology drug development market?
Industry trends
The majority of marketed disease-modifying neuroimmunology products are those approved for the treatment of MS. With over 20 different disease-modifying therapy (DMT) products available, companies are forced to contend with the complexities of a crowded market. There are many ways in which companies seek to differentiate their products, including frequency of administration, method of administration, and side-effect amelioration. Most patients who experience MS exacerbations face the prospect of life-long treatment. As such, the development of novel MOAs for this disease form is still a major focus of industry. For the non-MS indications, there are only a few neuroimmunology products currently approved.
Macroeconomic trends
The majority of marketed neuroimmunology products are of high cost, particularly in the US. The MS market in the US is beginning to see cost savings due to the launch of generic dimethyl fumarate. The launch of other generic and biosimilar agents over the next 10 years will help to keep rising costs in this market at bay.
Regulatory trends
Numerous diseases are either rare and/or have a high degree of unmet need for new treatment options. Hence, many of the associated neuroimmunological products have been assigned special designations to speed up and incentivize the development. To make drugs that treat rare diseases available more quickly, several country-specific key designations and processes exist.
Which are the key companies in the neuroimmunology drug development market?
The key companies in the neuroimmunology drug development market are F. Hoffmann-La Roche Ltd, Biogen, AstraZeneca, Johnson & Johnson, Merck KGaA, Novartis AG, Sanofi, UCB SA, Eisai Co Ltd, and Eli Lilly and Co.
F. Hoffmann-La Roche Ltd
It is a biotechnology company that provides pharmaceuticals for the treatment of cancer, other autoimmune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. In the neuroimmunology space, Roche has nine pipeline products in clinical development.
Biogen
It is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. In the neuroimmunology space, Biogen markets numerous products for MS.
AstraZeneca
It is a biopharmaceutical company that is focused on discovery, production, and commercialization of a range of prescription drugs. It develops products in therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection, and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals, and vaccines. In the neuroimmunology space, AstraZeneca’s main presence is through its subsidiary, Alexion Pharmaceuticals.
For more insights on neuroimmunology drug development market, download a free report sample
Market report scope
Key companies | F. Hoffmann-La Roche Ltd, Biogen, AstraZeneca, Johnson & Johnson, Merck KGaA, Novartis AG, Sanofi, UCB SA, Eisai Co Ltd, and Eli Lilly and Co |
This report provides:
- Overview of the neuroimmune system and its role in the pathology of eight key neurological diseases.
- Overview of key trends in the neuroimmunology drug development space.
- Evaluation of marketed and pipeline neuroimmunology drugs for the treatment of eight key neurological diseases, highlighting key mechanisms of action.
- Evaluation of clinical trials for marketed and pipeline neuroimmunology drugs.
- Market analysis of key neuroimmunology products in 2020 and 2025 plus an overview of key deals in the neuroimmunology space.
- Overview of opportunities and unmet needs in the neuroimmunology space.
- Analysis of companies developing neuroimmunology drugs, with a focus on major players.
Key Highlights
Report deliverable include a PowerPoint report.
Of the innovator products marketed for the eight key indications covered in this report, the majority are indicated for MS (23 drugs), followed by three each for NMOSD and AD, and two for MG. Most marketed neuroimmunology products are small molecules (12 drugs), followed by mAbs (nine drugs) and recombinant proteins (seven drugs).
According to GlobalData’s Drugs Database, there are currently almost 220 neuroimmunology drugs in Phase I, II, III, and later stages of development in the 8MM. The highest number of drugs are in development for AD (75 drugs), followed by amyotrophic lateral sclerosis (ALS) (39 drugs), PD (35 drugs), MS (26 drugs), and relapsing-remitting MS (RRMS) (26 drugs).
The top 20 neuroimmunology products were worth $20.1 billion in 2020 and are expected to be worth $26.6 billion by 2025. Growth is driven primarily by the continued uptake of Ocrevus in MS and new launches across several indications. Extensive deal-making is occurring within the neuroimmunology drug space, with the top-valued deal being the acquisition of Alexion Pharmaceuticals by AstraZeneca, announced in December 2020.
Of the ten key players involved in the neuroimmunology market, Roche, Biogen, AstraZeneca, Johnson & Johnson (J&J), Novartis, Sanofi, and UCB are all involved in marketing or developing neuroimmunology products across multiple neurological indications. The remaining three players are instead focused on neuroimmunological products in just one indication each—Merck KGaA in MS and Eisai and Lilly in AD.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of neuroimmunology pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global neuroimmunology drug market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neuroimmunology market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which are the key companies in the neuroimmunology drug development market?
The key companies in the neuroimmunology drug development market are F. Hoffmann-La Roche Ltd, Biogen, AstraZeneca, Johnson & Johnson, Merck KGaA, Novartis AG, Sanofi, UCB SA, Eisai Co Ltd, and Eli Lilly and Co.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.